Vertex pursues broader inaxaplin opportunity ahead of 2027 pivotal kidney-disease data

Vertex Pharmaceuticals is building a renal franchise around inaxaplin, a treatment candidate for APOL1-mediated kidney disease (AMKD), and is seeking to expand its potential addressable population beyond the initially targeted group of patients with two APOL1 risk variants and substantial proteinuria.

A recent mid-stage AMPLIFY study reportedly showed reductions in proteinuria and favorable kidney-function markers in broader AMKD groups, including patients with more modest proteinuria and those with diabetes. The result supports Vertex’s argument for a wider eventual label, though it is not yet confirmatory evidence.

The pivotal Phase 2/3 AMPLITUDE trial remains the central catalyst. Its interim analysis is expected in early 2027, after 48 weeks of treatment, and will assess kidney function (eGFR) and proteinuria. Positive data could support an accelerated-approval filing in the U.S.

Vertex has characterized the initially studied AMKD population as roughly 150,000 people in the U.S. and Europe; it believes the expanded cohorts could add about 100,000 more potential patients. Those estimates and any label expansion will ultimately depend on trial results and regulators.

The kidney strategy also includes povetacicept for IgA nephropathy and other B-cell-driven renal diseases, positioning Vertex for a broader move beyond its core cystic-fibrosis business.